Abstract
Background: Fatal overdoses involving fentanyl/fentanyl analogs (F/FA) have increased in the US, raising questions about naloxone doses for F/FA overdose reversal. Emergency medical services (EMS) data provide an opportunity to examine naloxone administration changes as fentanyl increases in the illicit opioid supply. Methods: Administered naloxone intranasal-equivalent total dose (INTD) in milligrams (mg) was calculated for Kentucky EMS suspected opioid overdose (SOO) encounters (n=33,846), 2018–2021, and patterns of administration were examined. County-level F/FA availability was measured as 1) proportion of fatal drug overdoses involving F/FA, and 2) F/FA police seizures. Linear mixed models estimated changes in INTD in relation to local F/FA availability accounting for patient characteristics. Results: From 2018–2021, SOOs increased by 44% (6853 to 9888) with an average INTD increase from 4.5 mg to 4.7 mg, with more than 99% of encounters resulting in successful reversal each year. For SOO encounters examined by outcome at the scene (i.e., non-fatal fatal vs fatal), average INTD for non-fatal were 4.6 mg compared to 5.9 mg for fatal overdoses. Mixed modeling found no significant relationship between INTD and the two measures for local F/FA availability. Conclusion: As F/FA-involved overdose risk increased, we observed a modest increase in INTD administered in SOO EMS encounters – just slightly higher than the 4 mg standard dose. The lack of significant relationship between F/FA and naloxone dose suggests that naloxone utilization in SOO with EMS involvement remains effective for overdose reversal, and that EMS naloxone dosing patterns have not changed substantially.
| Original language | English |
|---|---|
| Article number | 111062 |
| Journal | Drug and Alcohol Dependence |
| Volume | 255 |
| DOIs | |
| State | Published - Feb 1 2024 |
Bibliographical note
Publisher Copyright:© 2023
Funding
This research was supported by the National Institutes of Health through the NIH HEAL InitiativeSM under award UM1DA049406 (SLW) (ClinicalTrials.gov Identifier: NCT04111939) and the Centers for Disease Control (CDC) and Prevention through Partnership with Public Safety and First Responders under award NU17CE924971 (SS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the NIH HEAL InitiativeSM, or the CDC. This research was supported by the National Institutes of Health through the NIH HEAL Initiative SM under award UM1DA049406 (SLW) (ClinicalTrials.gov Identifier: NCT04111939) and the Centers for Disease Control ( CDC ) and Prevention through Partnership with Public Safety and First Responders under award NU17CE924971 (SS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, the NIH HEAL Initiative SM , or the CDC.
| Funders | Funder number |
|---|---|
| Public Safety and First Responders | NU17CE924971 |
| National Institutes of Health (NIH) | NCT04111939, UM1DA049406 |
| National Institutes of Health (NIH) | |
| Centers for Disease Control and Prevention | |
| Substance Abuse and Mental Health Services Administration |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Emergency Medical Services
- Fentanyl
- Naloxone
- Opioid Overdose
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver